| Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer? | |
| | |
MedLine Citation:
|
PMID: 11435015 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Suboptimally debulked patients with advanced ovarian cancer who are treated with a combination of cisplatin plus paclitaxel (TP therapy) have a better survival as compared to patients treated with a combination of cisplatin plus cyclophosphamide (CP therapy), but this advantage has not been demonstrated in optimally debulked patients. We performed a retrospective study to compare the effectiveness of TP therapy and CP therapy in optimally debulked patients. STUDY DESIGN: From 1991 to 1996, 87 consecutive patients with advanced ovarian cancer treated in the University Hospital Utrecht and the St. Antonius Hospital were included in the study. Overall survival (OS) of patients treated with TP or CP were compared. Multivariable Cox-regression analysis was used to calculate a hazard rate ratio (HRR) for OS. RESULTS: In the study period, 51 patients were treated with CP, and 36 patients were treated with TP. In the 18 patients with a tumorrest >2cm, there was a clear, but not statistically significant benefit from TP. In 69 patients with a tumorrest <or=2cm, life expectancy was not increased in patients treated with TP as compared to patients treated with CP (HRR 0.9 (95% CI 0.4-1.9)). CONCLUSION: We could not show that ovarian cancer patients with residual disease of <or=2cm who were treated with TP had better survival as compared to patients who were treated with CP. Taking into account the high costs of treatment with TP, a randomized trial comparing the effects of TP therapy and CP therapy in optimally debulked patients is warranted. |
| | |
Authors:
|
J P Roovers; E A Sijmons; J H van Leeuwen; B W Mol; P O Witteveen; P H Slee; A P Heintz |
Related Documents
:
|
18316345 - Response assessment in solid tumours: a comparison of who, swog and recist guidelines. 6761595 - Clinical controlled trial in advanced breast cancer: cmfv (cyclophosphamide, methotrexa... 12115355 - Phase ii trial of gemcitabine in advanced sarcomas. 21041705 - Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sust... 2297035 - Auditory function in duane's retraction syndrome. 679615 - Synovial rupture of the knee joint: confusion with deep vein thrombosis. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: European journal of obstetrics, gynecology, and reproductive biology Volume: 97 ISSN: 0301-2115 ISO Abbreviation: Eur. J. Obstet. Gynecol. Reprod. Biol. Publication Date: 2001 Jul |
Date Detail:
|
Created Date: 2001-07-03 Completed Date: 2001-09-13 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375672 Medline TA: Eur J Obstet Gynecol Reprod Biol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 80-4 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynecology, University Medical Center, Utrecht, The Netherlands. j.p.roovers@azu.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Cisplatin / therapeutic use* Combined Modality Therapy Cyclophosphamide / therapeutic use Female Humans Middle Aged Neoplasm Staging Ovarian Neoplasms / drug therapy*, mortality, surgery* Paclitaxel / therapeutic use* Prognosis Retrospective Studies Survival Rate |
| Chemical | |
Reg. No./Substance:
|
15663-27-1/Cisplatin; 33069-62-4/Paclitaxel; 50-18-0/Cyclophosphamide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Changes of collagen type III in female patients with genuine stress incontinence and pelvic floor pr...
Next Document: Estrogen changes mitosis orientation in the uterine epithelia.